ETV6-ACSL6 fusion gene in myeloid neoplasms: clinical spectrum, current practice, and outcomes.
Xia WuHao CaiYu QiuJian LiDao-Bin ZhouXin-Xin CaoPublished in: Orphanet journal of rare diseases (2020)
Patients with the ETV6-ACSL6 fusion gene mainly present with myeloproliferative and myelodysplastic disorders, typically with increased eosinophils and/or basophils and poor survival. Intensive therapies such as allogenic stem cell transplantation should be an initial consideration for eligible patients.
Keyphrases
- stem cell transplantation
- end stage renal disease
- acute lymphoblastic leukemia
- high dose
- acute myeloid leukemia
- bone marrow
- ejection fraction
- newly diagnosed
- copy number
- chronic kidney disease
- genome wide
- primary care
- peritoneal dialysis
- healthcare
- prognostic factors
- dendritic cells
- type diabetes
- adipose tissue
- patient reported outcomes
- immune response
- metabolic syndrome
- quality improvement
- patient reported
- glycemic control